SB
Surv BioPharma
Japan · Biotech
Surv BioPharma develops oncolytic virus therapies for cancer.
Product
Surv BioPharma develops genetically engineered viruses intended to replicate selectively in cancer cells and destroy them. Its platform uses a survivin-responsive promoter to control viral replication.
The Kagoshima University spinout is developing Surv.m-CRA-1 for rare bone and soft-tissue cancers. It is also working on a next-generation virus incorporating immune-related genes. The company was established in Japan in 2022 to commercialise research led by Ken-ichiro Kosai.
Funding history
4 rounds · 4 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Phased AMED GRiT support | ≤¥1.7B | Japan Agency for Medical Research and Development (AMED) — Participant | |
| Series B second close | ¥670M | FFG Venture Fund III — ParticipantFukuoka Jisho — ParticipantInnovation Kyoto 2021 Investment Limited Partnership — ParticipantOita VC Success Fund No. 7 — ParticipantSagin Venture Capital Fund No. 6 — ParticipantTOHO HOLDINGS CO — Participant | |
| AMED ecosystem programme support | ≤¥2.7B | Japan Agency for Medical Research and Development (AMED) — Participant | |
| Series B first close | ¥1.5B | KII No.3 Impact Fund — LeadDaiwa Taiwan-Japan BioVenture Investment Limited Partnership II — ParticipantFujita TT Impact Fund I — ParticipantHigin Venture Fund No. 3 Investment Limited Partnership — ParticipantKagoshima Value Up Investment Limited Partnership — ParticipantNVCC Fund 10 — ParticipantQB Fund II — Participant |